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Cancer initiating cells (CIC) or cancer stem-like cells (CSC) 
represent a small, distinct population of cancer cells best 
characterized by their high tumorigenicity. They undergo 
asymmetric cell division that results in repopulation of 
the bulk of the tumor and self-renewal. CICs are likely 
responsible for treatment failure and tumor recurrence, as 
they are highly resistant to traditional therapies, such as 
chemo- and radiotherapy (1). This resistance is partly due to 
their proliferative quiescence and increased anti-apoptotic 
features. Immune targeting is an emerging alternative 
approach, which may override these resistance mechanisms. 
However, relatively little is known about the interaction 
between CICs and immune cells that have the capacity to 
recognise and destroy not only the bulk of the tumor but 
also CICs. 
In squamous cell carcinoma of the head and neck 
(SCCHN), CICs have been identified as a subpopulation of 
CD44+ cells. In a recent publication (2), Lee et al. carried 
out a comparative study between the immune behaviour 
of CD44+ and CD44− cells in SCCHN. The CD44 
marker alone is not sufficient to define the CIC population 
without other markers. ALDH bright cells e.g., represent 
a subpopulation of CD44+ cells displaying enhanced 
clonogenic, tumorigenic capacity and radioresistance (3). 
Nevertheless, the study (2) provides some novel information 
about potential enhanced immunosuppressive features of 
the CIC-containing population of tumor cells. The key 
observation is the preferential expression of the immune 
checkpoint molecule programmed death-ligand 1 (PD-L1) 
on CD44+ vs. CD44− SCCHN cells. PD-L1 binds to PD-1 
on T cells, inhibiting their function. In this study, IFNȖ 
secretion by autologous CD8+ tumor-iniltrating lymphocytes 
(TIL) was inhibited by CD44+ cells. In another study, using 
a SCCHN cell line, CD44+ cells have also been shown to 
produce more TGFȕ and IL-8, but not TNFα and IL-6, 
compared to that by CD44− cells (4). These CD44+ cells 
also inhibited T cell proliferation more strongly than CD44− 
tumor cells. However, neither study addressed the question of 
how susceptible these tumor cells are to T cell killing. Highly 
differentiated cytotoxic T lymphocytes (CTL) can be fairly 
resistant to immunosuppression, thus the effect of CD44+ 
tumor cells on CTL effector function would have been a more 
relevant T cell function to study. Indeed, it has been shown 
that SCCHN CICs, grown in 3D spheroids and identiied by 
elevated ALDH levels, Nanog, Sox and Oct3/4 expression, are 
more susceptible to allo-speciic T cell killing than tumor cells 
that are lower or negative for these markers (5). 
Successful targeting of CICs by antigen-specific T cells 
in other types of cancer has also been demonstrated. Novel/
mutated, overexpressed, oncofoetal, post-translationally 
altered and cancer testis (CT) are types of tumor-
associated antigens T cells recognize (6). In the SCCHN 
study, discussed above (2), the cognate antigens were not 
identiied so the question remains whether the proportions 
of tumor cells were comparable in the CD44+ and CD44− 
populations and if they differed in their antigen profile. 
As antibody blockade of the PD-1/PD-L1 interaction 
only partially reversed the inhibitory effect on autologous 
TIL-derived T cells, this possibility cannot be excluded. 
Biomarkers of CICs (e.g., ALDH1 or CD133) are also being 
investigated as immune targets (7). ALDH1A1-specific 
CD8+ T cells were shown to kill ALDH (bright) SCCHN 
CICs in vitro and T cell transfer resulted in better tumor 
control in vivo (8). However, the variety and reliability of 
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markers associated with CICs, along with the potential 
for damaging healthy stem cells, expressing stem-related 
markers, may detract from this approach. CT antigens have 
been found to be frequently expressed in SCCHN (9), with 
e.g., MAGE A3/6 being an independent prognostic factor 
for tumor recurrence. Thus, CTL or monoclonal antibodies 
targeting CT antigens may be effective against both CICs 
and non-CICs in SCCHN. Interestingly, some antigens 
speciic to CICs (e.g., BORIS, DNAJB8) have been reported 
to be more immunogenic than “shared” antigens (10,11). On 
the other hand, CD271+ melanoma CICs frequently lack 
the expression of melanoma tumor antigens TYR, MART1 
and MAGE C1/C2 (12). This means that targeting these 
antigens would not affect CIC survival.
The antigen presentation ability of CICs, enabling 
interactions between cytotoxic T cells and peptide-HLA/
MHC complexes, is also under debate. Low HLA class I 
expression and defective antigen processing machinery have 
previously been reported in CICs, in common with healthy 
stem cells (13). Contrastingly, Lee et al. reported that 
CD44+ and CD44− cells expressed comparable, high levels 
of HLA-ABC in the presence or absence of IFNȖ (2). This 
suggests the differences in T cell modulation by CD44+ 
and CD44− cells may not be associated with their antigen 
processing ability. It may be useful to extend this line of 
investigation by e.g., transfecting CD44+ and CD44− cells 
with a surrogate antigen and determine the cognate T cell 
response. 
A successful adaptive immune response, in which effector 
T cells eliminate CICs in an overt tumor and memory T 
cells persist to eliminate emerging CICs, would be crucial to 
achieve long-term tumor control. However, the interaction 
between tumor-infiltrating immune cells and CICs is still 
poorly understood as most studies are conducted in vitro 
rather than in situ. Whilst numerous immunosuppressive 
mechanisms have been attributed to CICs (14), most of 
these mechanisms are not unique to this population of 
cancer cells. There is a possibility that CICs are immune-
protected rather than being immunosuppressive in their 
own right. CICs reside within cellular ‘niches’, which aid 
their immune protection and survival. These may include 
enhanced chemoattraction of tumor-associated macrophages 
(TAM) by CICs and skewing towards immunosuppressive 
M2-type macrophages (15,16). In SCCHN, self-renewal 
of CICs, identified by CD44 and ALDH expression, has 
been promoted by endothelial cell-secreted factors (17). 
Furthermore, 80% of these CICs were found in close 
proximity to blood vessels in the tumor tissue. Elimination 
of tumor-associated endothelial cells significantly reduces 
the proportion of CICs in xenografts (17). These indings 
indicate that endothelial cell-initiated signaling can enhance 
the survival and self-renewal of CICs, providing a unique, 
protective microenvironment for these cells. 
The observation that PD-L1 is expressed on some 
CD44+ cells (but not on CD44− cells) in SCCHN (2) 
seems to confirm the theory that CICs are associated with 
enhanced immune protection. PD-1/PD-L1 inhibition as a 
therapeutic target in SCCHN is being tested in numerous 
clinical trials both alone and in combination (18). PD-L1 
can also be expressed on infiltrating immune cells, as an 
effect of e.g. stromal factors, as shown by Spary et al. (19). 
However, correlation between PD-L1 expression on 
tumor cells or immune infiltrates and response to therapy 
has not been confirmed (20). Nevertheless, PD-L1 
targeting maybe crucial for releasing the full potential of 
tumor antigen-specific effector T cells to target not only 
PD-L1+ differentiated tumor cells but also CICs and 
immunosuppressive TAMs. 
As a conclusion, further studies with more precise 
identification of CICs and better definition of both their 
immunosuppressive nature and susceptibility to immune 
attack are clearly needed. Future treatment combinations 
may be improved by simultaneous targeting of the 
microenvironment, immune checkpoints, CICs and the 
bulk of the tumor in order to deliver direct and indirect hits 
both for tumor destruction and protection from recurrence. 
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